21 min listen
Complement and Neonatal Fc Receptor Inhibitors in Myasthenia Gravis, Highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) Trials
FromAmerican Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)
Complement and Neonatal Fc Receptor Inhibitors in Myasthenia Gravis, Highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) Trials
FromAmerican Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)
ratings:
Length:
67 minutes
Released:
Dec 13, 2022
Format:
Podcast episode
Description
Dr. Elie Naddaf, MD interviews Dr. James Howard, MD about the use of complement and the neonatal Fc receptor inhibitors in myasthenia gravis, highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials.
Released:
Dec 13, 2022
Format:
Podcast episode
Titles in the series (100)
Axillary Pain as a Heralding Sign of Neoplasm Involving the Upper Thoracic Root by American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM)